Find Pridopidine manufacturers, exporters & distributors on PharmaCompass

Pridopidine

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

14 Drugs in Development

14 Drugs in Development

INTERMEDIATES

2 Intermediates Suppliers

2 Intermediates Suppliers

DIGITAL CONTENT

7 NEWS #PharmaBuzz

media
7 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 346688-38-8, 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine, Acr16, Acr-16, 4-(3-methylsulfonylphenyl)-1-propylpiperidine

Molecular Formula

C₁₅H₂₃NO₂S

Molecular Weight

281.4 g/mol

InChI Key

YGKUEOZJFIXDGI-UHFFFAOYSA-N

FDA UNII

HD4TW8S2VK

Pridopidine has been used in trials studying the treatment of Huntington's Disease.

1 2D Structure

Pridopidine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-(3-methylsulfonylphenyl)-1-propylpiperidine

2.1.2 InChI

InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3

2.1.3 InChI Key

YGKUEOZJFIXDGI-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C

2.2 Other Identifiers

2.2.1 UNII

HD4TW8S2VK

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine

2. 4-(3-methanesulfonylphenyl)-1-propylpiperidine

3. Acr16 Compound

4. Huntexil

2.3.2 Depositor-Supplied Synonyms

1. 346688-38-8

2. 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine

3. 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine

4. Acr16

5. Acr-16

6. 4-(3-methylsulfonylphenyl)-1-propylpiperidine

7. Hd4tw8s2vk

8. Chembl596802

9. Fr310826

10. Unii-hd4tw8s2vk

11. Acr16 Compound

12. Acr 16

13. Pridopidine [usan]

14. Pridopidine [usan:inn]

15. Pridopidine [mi]

16. Pridopidine [inn]

17. Pridopidine (usan/inn)

18. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine

19. Pridopidine [who-dd]

20. Schembl166748

21. Asp2314

22. Dtxsid90188225

23. Bdbm50308028

24. Mfcd09835586

25. Zinc22063703

26. Akos015891431

27. Db11947

28. Ncgc00386586-01

29. As-50146

30. Hy-10684

31. Db-014417

32. Cs-0002733

33. Ft-0672149

34. 4-(3-methanesulfonylphenyl)-1-propylpiperidine

35. D09953

36. O11067

37. Q7242858

38. Piperidine, 4-(3-(methylsulfonyl)phenyl)-1-propyl-

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₂₃NO₂S
Molecular Weight	281.4 g/mol
XLogP3	2.6
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	4
Exact Mass	281.14495015 g/mol
Monoisotopic Mass	281.14495015 g/mol
Topological Polar Surface Area	45.8 Å²
Heavy Atom Count	19
Formal Charge	0
Complexity	366
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in huntington's disease and schizophrenia and schizoaffective disorders.

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

ACR16 belongs to a novel class of drugs, characterised as dopaminergic stabilisers, CNS active compounds that can both enhance and counteract dopaminergic effects in the brain depending on the initial level of dopaminergic activity. ARC16 works to "smooth" the many functions of this neurotransmitter chemical in striatum and other areas of the brain. Thus they have the ability to stabilize behavioural and motor disturbances caused by neurological and psychiatric disorders. They do this in pathological states without compromising normal thought processes or motor functions.

Drugs in Development